Alkem laboratories has announced a timing change for its upcoming conference call to discuss Q3FY26 and 9MFY26 financial results. The pharmaceutical company informed stock exchanges on February 12, 2026, that the call has been rescheduled from 4:00 PM to 5:00 PM IST on Friday, February 13, 2026.

Conference Call Details

The revised conference call will run from 5:00 PM to 6:00 PM IST and will follow the announcement of the company's Q3 and 9MFY26 financial results on the same day. Motilal Oswal Securities Ltd. will host the investor and analyst call.

Management Participation

Alkem Laboratories will be represented by senior leadership during the call:

• Dr. Vikas Gupta - Chief Executive Officer
• Mr. Nitin Agrawal - Chief Financial Officer

Dial-in Information

The company has provided comprehensive dial-in details for participants across different regions:

Registration and Contact Information

Participants can use the Express Join with Diamond Pass registration system for streamlined access. The company recommends dialing in 10 minutes ahead of the scheduled start time.

For investor relations queries, participants can contact:

• Purvi Shah / Isha Trivedi (Alkem Laboratories): +91 84337 00890 / 98925 90003
• Tushar Manudhane (Motilal Oswal Securities): +91 22 6129 1536 / +91 82911 38039

This revision follows the company's earlier intimation dated January 23, 2026, and has been communicated to both BSE Limited and National Stock Exchange of India Limited in compliance with SEBI listing regulations.

Alkem Laboratories has formalized its corporate restructuring initiative with the board of directors of Alkem Medtech Private Limited officially approving the merger on February 6, 2026. The pharmaceutical company's wholly-owned subsidiary board has given formal consent for merging Alkem Medtech Ortho Private Limited with Alkem Medtech Private Limited through a scheme of arrangement.

Merger Structure and Financial Details

The proposed merger involves consolidation of two subsidiaries operating in the medical technology space, with significant differences in their financial positions. The board's approval represents a formal step in the corporate restructuring process under Sections 230 to 232 of the Companies Act, 2013.

Business Operations and Rationale

The transferor company, Alkem Medtech Ortho Private Limited, is primarily engaged in manufacturing, producing, trading, importing and exporting orthopedic surgery equipment and joint implants. The transferee company, Alkem Medtech Private Limited, operates in manufacturing, importing, exporting and marketing of medical, surgical and dental equipment.

Regulatory Approval Process

The merger requires sanction from both Mumbai and Ahmedabad benches of the National Company Law Tribunal (NCLT). The scheme is subject to requisite approvals from shareholders and creditors if directed by NCLT, along with compliance with applicable laws and other required approvals.

Strategic Impact

The consolidation will eliminate multiplicity of legal and regulatory compliances while creating a streamlined management structure. The combined entity will possess a broader product portfolio, strengthening its presence in key therapeutic segments and geographic markets through optimized distribution networks.